ICI therapy is a leading research direction of tumor immunotherapies, with the most representative ICI being programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors and cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors. Here, PDCD1 is linked to neoplasm.